Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy

American Medical Association, JAMA Dermatology, 2(158), p. 189, 2022

Journal article published in 2022 by Kimberly Tang, Jayhyun Seo, Bruce C. Tiu, Thomas K. Le, Vartan Pahalyants, Neel S. Raval, Pearl O. Ugwu-Dike, Leyre Zubiri, Vivek Naranbhai, Mary Carrington, Alexander Gusev, Kerry L. Reynolds, Nicole R. LeBoeuf, Maryam M. Asgari, Shawn G. Kwatra and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving forbidden

Published version: archiving forbidden

Policy details

Data provided by